<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073850</url>
  </required_header>
  <id_info>
    <org_study_id>KUGH12078-001</org_study_id>
    <nct_id>NCT03073850</nct_id>
  </id_info>
  <brief_title>Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation</brief_title>
  <acronym>ATEMS-AF</acronym>
  <official_title>Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation (The ATEMS-AF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the best strategy for long-term stroke prevention&#xD;
      in patients who have sinus rhythm after a successful catheter ablation for atrial&#xD;
      fibrillation (AF) and who are at risk of thromboembolic events (CHA2DS2-VASc score â‰¥2). The&#xD;
      investigators are going to compare antiplatelet therapy to oral anticoagulation (OAC) with&#xD;
      different doses of edoxaban (30mg and 60mg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that the strategy of OAC will be superior to antiplatelet&#xD;
      therapy, but low dose edoxaban (30mg) will be non-inferior to standard dose edoxaban (60mg)&#xD;
      for reducing the risk of stroke or systemic embolism in patients who underwent successful AF&#xD;
      ablation. Although AF ablation is an effective therapy for reducing and/or eliminating the&#xD;
      burden of AF, there may continue to be a risk of late recurrence or asymptomatic recurrence&#xD;
      of atrial tachyarrhythmias. Until now, the guideline has recommended the continuation of OAC&#xD;
      in patients who are at risk of stroke or systemic embolism based on the CHA2DS2-VASc score,&#xD;
      even though they have maintained sinus rhythm. The annual rate of stroke, however, is still&#xD;
      lower compared to that predicted by the scoring system, because AF ablation reduced the AF&#xD;
      burden by 86% and the remaining episodes were significantly shorter in duration (median 6&#xD;
      minutes) than those pre-ablation reported by the previous study. Based on recent studies&#xD;
      which demonstrated that both standard-dose and low-dose non-vitamin K OACs (NOAC) performed&#xD;
      equally well with regard to the stroke prevention in patients with AF, low dose NOACs may&#xD;
      also be sufficient for stroke prevention of briefly lasting AF episodes after successful AF&#xD;
      ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Majority of enrolled patients have withdrawn.&#xD;
  </why_stopped>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom rate of stroke or systemic embolism during 2 years after successful AF ablation procedure</measure>
    <time_frame>2 year</time_frame>
    <description>Check stroke or systemic embolism through neurologic examination or imaging studies</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose OAC therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban of 30mg (Reduced dose of 15mg if body weight &lt; 60kg, CCr&lt; 50 ml/min, concomittant use of P-gp)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose OAC therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edoxaban of 60mg (Reduced dose of 30mg if body weight &lt; 60kg, CCr&lt; 50 ml/min, concomittant use of P-gp)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet</intervention_name>
    <description>ASA or clopidogrel</description>
    <arm_group_label>Antiplatelet therapy</arm_group_label>
    <other_name>aspirin 100mg or clopidogrel 75mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose oral anticoagulant</intervention_name>
    <description>Edoxaban of 30mg</description>
    <arm_group_label>Low-dose OAC therapy</arm_group_label>
    <other_name>Edoxaban of 30mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose oral anticoagulant</intervention_name>
    <description>Edoxaban of 60mg</description>
    <arm_group_label>Standard-dose OAC therapy</arm_group_label>
    <other_name>Edoxaban of 60mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients without evidence of any clinically apparent arrhythmia recurrence during at&#xD;
             least six months after last catheter ablation of AF.&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not meet all of the above listed inclusion criteria.&#xD;
&#xD;
          -  Patients with significant valvular heart disease or mechanical valve.&#xD;
&#xD;
          -  Patients with hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Patients with chronic renal impairment with creatinine clearance rate of &lt; 30 mg/dl.&#xD;
&#xD;
          -  Patients with contraindication to long-term OAC.&#xD;
&#xD;
          -  Patients who had a stroke within one year prior to enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Euy Lim, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>September 5, 2020</last_update_submitted>
  <last_update_submitted_qc>September 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hong Euy Lim, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

